AVAGENESIS CORP. APPOINTS IR CONSULTANT

February 3, 2015 – Calgary, Alberta: Avagenesis Corp. ("**Avagenesis**" or the "**Company**") (TSXV: VVA), is pleased to announce that it has retained the California-based firm of San Diego Torrey Hills Capital, Inc. ("Torrey") to conduct investor relations activities on behalf of the Company.

Headed by Mr. Clifford Mastricola, Torrey is an investor and financial public relations firm specializing in introducing small-cap companies to broader institutional and retail investor audiences. Pursuant to an agreement dated February 3, 2015 (the "Agreement") between the Company and Torrey, the Company will pay Torrey a monthly fee of US$5,000 for the two-month term of the Agreement.

The Company will also reimburse Torrey for expenses incurred in performing its services to the Company. The Agreement is subject to the approval of the TSX Venture Exchange. Torrey does not currently have any interest, directly or indirectly, in the Company or its securities. Neither Torrey nor Mr. Mastricola has any right or intent to acquire any interest, directly or indirectly, in the Company or its securities. Torrey does not intend to undertake any market making activities.

About Avagenesis Corp.

Avagenesis is a biotechnology company engaged in the commercialization of medical technologies for use in the practice of regenerative medical aesthetics. Avagenesis' development activities are focused on the complex task of efficiently isolating high quality, viable and potent adipose-derived adult stem cells and regenerative cells.

Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully execute its development, marketing and business development activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Material factors and assumptions in this press release include the ability of Avagenesis to successfully execute its development, marketing and business development activities. Avagenesis cautions the reader that the above list of risk factors is not exhaustive.

The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Further Information

For further information, please contact:

Avagenesis Corp.
Alan Tam, PFP, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575